美多芭联合tDCS治疗PD的疗效及对UPDRS评分的影响分析

Analysis of curative effect of madopar combined with t DCS in the treatment of PD and effect on UPDRS score

目的探讨美多芭联合经颅直流电刺激(t DCS)治疗帕金森(PD)的疗效及对PD综合评分量表(UPDRS)评分的影响。方法将本院2016年3月至2017年3月期间收治的94例PD患者根据随机数字法分为试验组和对照组,试验组给予美多芭联合t DCS治疗,对照组给予美多芭治疗,分别于治疗前、治疗后7d及1个月对UPDRS评分、治疗效果以及不良反应等进行综合评价。结果治疗1个月后,试验组患者的治疗总有效率为82.98%显著高于对照组的72.34%,组间比较差异有统计学意义(P<0.05)。对照组失眠2例,便秘2例,头晕3例,体位性低血压2例,不良反应发生率为23.40%。试验组失眠4例,便秘1例,头晕5例,体位性低血压1例,不良反应发生率为19.15%,两组的不良反应发生率(P>0.05);治疗7d及1个月后,试验组UPDRSⅠ、Ⅱ、Ⅲ及总的评分均低于对照组,组间差异有统计学意义(P<0.05)。结论对PD患者采用美多芭联合t DCS治疗方案,能显著改善患者的UPDRS评分,且该法具有较高的临床安全性,今后可能成为有潜力的PD治疗方法。

Objective To investigate the curative effect of madopar combined with tDCS in the treatment of Parkinson＇s disease （ PD ） and effect on UPDRS score. Method Ninety-four patients with PD who were treated in hospital from March 2016 to March 2017, were randomly divided into experimental group and control group, the experimental group was given madopar combined with transcranial direct current stimulation （ tDCS ） treatment, and the control group was given madopar treatment. The UPDRS score, treatment effect and adverse reactions were comprehensively evaluated before treatment, 7d and 1 month after treatment. Results After 1 month of treatment, the total effective rate in the experimental group was 82.98%, which was significantly higher than 72.34% in the control group, there was significant difference between the groups （ P〈0.05 ） ; There were 2 cases of insomnia, 2 cases of constipation, 3 cases of dizziness and 2 cases of postural hypotension in the control group, and the incidence of adverse reaction was 23.40%; There were 4 cases of insomnia, 1 cases of constipation, 5 cases of dizziness and 1 cases of postural hypotension in the control group, and the incidence of adverse reaction was 19.15%; The incidence of adverse reactions of the two groups had no significant difference （ P〉0.05 ） ; After treatment for 7d and 1 month, the scores of UPDRS, I, II, III and total score in the experimental group were lower than those in the control group, the difference was statistically significant （P〈0.05） . Conclusion Treatment prescription of madopar combined tDCS treatment for PD patients, can significantly improve the patient＇s UPDRS score, and the method has high clinical safety and may become a potential treatment for PD in the future.